11 results
P
Yu X, Xu R, Zhang Z, Yang Y, Deng F
I/C
extra-short implants (≤ 6 mm), longer implants (≥ 8 mm)
O
bone augmentation
P
Li QL, Yao MF, Cao RY, Zhao K, Wang XD
I/C
short dental implants, splinted and nonsplinted prostheses
O
survival rates
P
Hu ML, Zheng G, Lin H, Yang M, Zhang YD, Han JM
I/C
Desensitizing Toothpastes
O
Dentine Hypersensitivity
P
E2F4, FOXM1, TFDP1, E2F1, SIN3A, JUN, DDX4, FOSL1, NOC2L, HMGA1, CDK1, CCNB1, AURKA, CDC20, CCNA2, SCNN1A, CDCA3, SOX6
I/C
O
survival prognosis, immune infiltrations, diagnostic efficacy
P
patients with sleep complaints
I/C
Tai Chi, non-treatment and active treatment groups
O
Pittsburgh Sleep Quality Index (PSQI)
P
red yeast rice preparations
I/C
RYR preparations, control treatments
O
adverse health outcomes
P
COVID-19 patients
I/C
3-drugs-3-formulas, conventional treatment
O
duration of fever, cough, fatigue, length of hospital stay, time for nucleic acid conversion, aggravation rate, mortality, recovery rate of chest computerized tomography manifestations, total effectiveness
P
Dr. Heinrich, colleagues
I/C
systematic review and meta-analysis, the literature screening principles, outcome data collection, and the cohort studies included in the sub-group analysis
O
their review and suggestions
P
Orthodontic-surgical treatment patients
I/C
Conventional combined orthodontic-surgical treatment, No treatment or alternative treatments
O
Oral health-related quality of life
P
8050 patients
I/C
Cyclosporine + methotrexate + Anti-T cell globulin (ATG), tacrolimus + methotrexate + ATG, tacrolimus + bortezomib + sirolimus, cyclosporine + marrow mesenchymal stem cells (MMSCs), corticosteroids alone
O
proportion of patients who respond to therapies